Binding Model for Nonpeptide Antagonists of αvβ3 Integrin
- 7 November 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (26) , 5640-5648
- https://doi.org/10.1021/jm0203130
Abstract
A binding model for nonpeptide antagonists of integrin alpha(v)beta(3) has been developed through docking analyses utilizing the MMFFs force field and the recently published crystal structure, 1JV2. Results of this docking study have led to the identification of a novel binding model for selective antagonists of alpha(v)beta(3) over alpha(IIb)beta(3) integrins. Four different chemical classes are shown to bind in a similar fashion providing a measure of confidence in the proposed model. All alpha(v)beta(3) and alpha(IIb)beta(3) antagonists have a basic nitrogen separated some distance from a carboxylic acid to mimic RGD. For the alpha(v)beta(3) antagonists under present consideration, these charged ends are separated by twelve bonds. The basic nitrogen of the active alpha(v)beta(3) ligands are shown to interact with D150 of alpha(v) and the ligands' carboxylic acid interact with R214 of beta(3) while adopting an extended conformation with minimal protein induced internal strain. In addition, an energetically favorable interaction is found with all of the active alpha(v)beta(3) molecules with Y178 of alpha(v) when docked to the crystallographically determined structure. This novel interaction may be characterized as pi-pi stacking for the most active of the alpha(v)beta(3) selective antagonists. The proposed model is consistent with observed activity as well as mutagenicity and photoaffinity cross-linking studies of the alpha(v)beta(3) integrin.Keywords
This publication has 18 references indexed in Scilit:
- Resolution of Lung Inflammation by CD44Science, 2002
- Nonpeptide αvβ3 antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideBioorganic & Medicinal Chemistry Letters, 2002
- Identification of a Contact Domain between Echistatin and the Integrin αvβ3by Photoaffinity Cross-LinkingBiochemistry, 2001
- Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclastsJournal of Clinical Investigation, 2000
- Hematologically Important Mutations: Glanzmann ThrombastheniaBlood Cells, Molecules, and Diseases, 1997
- Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.Journal of Clinical Investigation, 1997
- The Amino-terminal One-third of αIIb Defines the Ligand Recognition Specificity of Integrin αIIbβ3Published by Elsevier ,1996
- A novel divalent cation-binding site in the a domain of the ?2 integrin CR3 (CD11b/CD18) is essential for ligand bindingCell, 1993
- A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.Journal of Clinical Investigation, 1992
- A β 3 Integrin Mutation Abolishes Ligand Binding and Alters Divalent Cation-Dependent ConformationScience, 1990